Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bambang S Adiwijaya

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Molecular Biosystems|January 12, 2007
Biological network design strategies: discovery through dynamic optimizationBambang S Adiwijaya, Paul I Barton, Bruce Tidor
Plos Computational Biology|January 14, 2012
A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infectionBambang S Adiwijaya, Tara L Kieffer, Joshua Henshaw, et al.
Antiviral Therapy|July 7, 2009
Rapid decrease of wild-type hepatitis C virus on telaprevir treatmentBambang S Adiwijaya, Brian Hare, Paul R Caron, et al.
Molecular Cancer Therapeutics|August 28, 2015
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer ModelMichael D Curley, Gauri J Sabnis, Lucia Wille, et al.
Plos Computational Biology|April 27, 2010
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variantsBambang S Adiwijaya, Eva Herrmann, Brian Hare, et al.
The Journal of Infectious Diseases|July 22, 2008
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjectsDoug J Bartels, Yi Zhou, Eileen Z Zhang, et al.
British Journal of Cancer|October 27, 2018
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation studyPamela Munster, Ian E Krop, Patricia LoRusso, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Molecular Biosystems|January 12, 2007
Biological network design strategies: discovery through dynamic optimizationBambang S Adiwijaya, Paul I Barton, Bruce Tidor
Plos Computational Biology|January 14, 2012
A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infectionBambang S Adiwijaya, Tara L Kieffer, Joshua Henshaw, et al.
Antiviral Therapy|July 7, 2009
Rapid decrease of wild-type hepatitis C virus on telaprevir treatmentBambang S Adiwijaya, Brian Hare, Paul R Caron, et al.
Molecular Cancer Therapeutics|August 28, 2015
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer ModelMichael D Curley, Gauri J Sabnis, Lucia Wille, et al.
Plos Computational Biology|April 27, 2010
A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variantsBambang S Adiwijaya, Eva Herrmann, Brian Hare, et al.
The Journal of Infectious Diseases|July 22, 2008
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjectsDoug J Bartels, Yi Zhou, Eileen Z Zhang, et al.
British Journal of Cancer|October 27, 2018
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation studyPamela Munster, Ian E Krop, Patricia LoRusso, et al.
Pageof 1